Canadian marijuana producer Tilray Inc. says it has received approval from the U.S. Drug Enforcement Administration agency to export a medical cannabis product south of the border for use in a clinical trial.
The company and a researcher at the University of California San Diego believe this is the first export of a cannabis product from a Canadian company to the U.S., where marijuana is still illegal at the federal level.
Tilray will be exporting capsules containing a formulation with two active ingredients extracted from the cannabis plant for a clinical trial examining the drug as a potential treatment for adults with essential tremor.
Get weekly health news
The formulation will contain cannabidiol and tetrahydrocannabinol, better known as CBD and THC, and will be used in a trial scheduled to begin in early 2019.
WATCH: How to buy weed in Canada when it’s legalized
- Ontario man dead after canoe capsizes, 2 B.C. people missing after falling off paddle boards
- Winning Lotto 6/49 Gold Ball jackpot ticket worth $16M sold in Peterborough
- Quebec’s national library moves ahead with AI cultural databank project
- Race to build Canada’s next submarine fleet enters its final stretch
-
![]()
B.C. investigator reveals gang letter claimed 1,000 foot soldiers linked to extortion network -
![]()
“Canada strong will help make American great again”: Carney pitches to Economic Club of New York -
![]()
Kingston family speaks out after boy dies following allergic reaction -
![]()
Police investigate prolonged disappearance of missing girl found safe
UC San Diego’s Dr. Fatta Nahab said he believes this product has not been imported from Canada into the U.S. before.
While several states have legalized cannabis for medical or recreational use, marijuana remains illegal under U.S. federal law.
Comments
Want to discuss? Please read our Commenting Policy first.